Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akero Therapeutics Inc AKRO

Healthcare Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing... see more

Recent & Breaking News (NDAQ:AKRO)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire October 19, 2023

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

GlobeNewswire October 17, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire October 17, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire October 16, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire October 14, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile October 10, 2023

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

GlobeNewswire October 10, 2023

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

GlobeNewswire October 9, 2023

Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology

GlobeNewswire October 4, 2023

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

GlobeNewswire August 31, 2023

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

GlobeNewswire August 28, 2023

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 11, 2023

Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology

GlobeNewswire June 23, 2023

Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

GlobeNewswire June 5, 2023

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

GlobeNewswire June 1, 2023

Akero Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

GlobeNewswire May 16, 2023

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 15, 2023

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

GlobeNewswire March 29, 2023

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 17, 2023